Abstract: Objective To compare the therapeutic effects between continuous subcutaneous insulin infusion (CSII) plus metformin and CSII plus pioglitazone in shortterm T2DM. Methods73 hospitalized patients with short term T2DM were randomly divided into three groups: simple CSII group, CSII plus metformin group, CSII plus pioglitazone group.All cases were treated for 2 weeks, then,fasting plasma glucose(FPG), insulin(Ins), C-peptide(C-P) and high sensitivity CRP(hsC-RP) were measured and postprandial glucose(PG),Ins, CP, hsCRP were measured at 2h after taking 75g glucose. Steadystate model βcell function (HOMA-β) and insulin resistance index (HOMA-IR)were calculated.The treatment costs and changes of above indicators before and after therapy were compared among three groups. Results HOMAβ levels were increased(P<0.05), HOMA-IR levels decreased significantly(P<0.05) in metformin and pioglitazone groups compared with simple CSII group.The glucose target time and treatment costs were reduced, and insulin dosage decreased significantly in metformin group compared with the simple CSII and pioglitazone groups(P<0.05). ConclusionsCompared with simple CSII,CSII plus metformin or pioglitazone could improve the function of pancreatin βcell and reduce IR. CSII plus with metformin versus pioglitazone could decrease insulin dosage and treatment costs and shorten hospitalization period.